Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity. GLP-1 agonists are a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity. The company will launch generic semaglutide injection under the brand name -- Noveltreat, after the expiry of semaglutide patent in India. The product has received approval from the DCGI following a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths - 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg once weekly. The product is administered via an easy-to-use prefilled pen, designed to support convenient and accurate dosing.

In December 2025, the company had secured approval from DCGI for manufacturing and marketing semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It will be launched under the brand name -- Sematrinity, after the expiry of semaglutide patent in India.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.